ACR 2016 The Crossroads of Radiology

ACR2016VM37 - Update on Imaging of Chronic Liver Disease

May 17, 2016 10:00am ‐ May 17, 2016 12:00pm


The purpose of the session is to provide an update on imaging of chronic liver disease which is very prevalent in the United States. Grey-scale ultrasound findings of chronic diffuse liver disease and cirrhosis will be discussed. Because of the increased risk of hepatocellular carcinoma in patients with chronic liver disease, the role of surveillance ultrasound and use of contrast-enhanced ultrasound immediately after detection of a nodule will also be discussed. In addition, the session will focus on the importance of quantifying liver fibrosis in the patient with chronic liver disease, ultrasound elastography, magnetic resonance elastography and emerging technologies for the care of the patient with chronic liver disease. Developed in conjunction with the Society of Radiologists in Ultrasound.

Learning Objectives:

  1. Identify the role and limitations of grey scale ultrasound in evaluating the patient with chronic diffuse liver disease and cirrhosis.
  2. Distinguish the role of CEUS in evaluating a nodule detected during ultrasound surveillance of the liver in the patient with chronic liver disease.
  3. Define the emerging technologies of US and MR elastography and their role in evaluating the patient with chronic liver disease.


  • Gastrointestinal


  • Ultrasound




  • Leslie Scoutt: None

  • Richard Barr: Speakers Bureau-Phillips Healthcare|Siemens Healthcare|SuperSonic Imagine; Research Grants-Phillips Healthcare|Siemens Healthcare|Hitachi Aloka Medical Ltd|Analogic|SuperSonic Imagine

  • Richard Ehman: Royalty Income-Mayo Clinic / Resoundant; Officer, Director-Resoundant: President, CEO, Equity holder; Research Grants-Resoundant

  • Anil Kurup: None

  • Stephanie Wilson: None

You must be logged in and own this session in order to post comments.